Overview
- Published June 2, 2026, the Journal of Virology paper reports that depleting the host trafficking protein Rab11B blocked binding and entry of recent H3N2 influenza A isolates in human lung cell experiments.
- The same experiments showed H1N1 isolates were unaffected, and reverse genetics mapped the defect to an H3N2-specific role for Rab11B during the entry step.
- The work used clinical isolates taken from nasal swabs in 2022 and was carried out in cell-culture systems rather than in animals or people, so the result does not demonstrate clinical benefit or safety.
- Because Rab11B is a host protein, the finding suggests a host-directed route for new antivirals but raises questions about specificity and side effects that require extensive preclinical testing.
- The authors say their next steps are to test whether Rab11B-dependency is common across H3N2 lineages and to define Rab11B’s exact molecular role, outcomes that will determine whether this leads to new diagnostics or treatments.